Patents by Inventor Joan Fernandez Esmerats

Joan Fernandez Esmerats has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors
    Patent number: 11976279
    Abstract: This disclosure relates to the use of miRNA-483 and its target genes, UBE2C, pVHL and HIF1alpha, in managing the treatment of cardiovascular and inflammatory diseases. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a miR-483 mimic and/or an HIF inhibitor and a pharmaceutically acceptable excipient for use in treating or preventing a vascular disease or condition. In certain embodiments, the miR-483 mimic is a double stranded nucleobase polymer or an expression vector that expresses mature human miR-483-5p and miR-483-3p sequences or operable fragments and variants.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: May 7, 2024
    Assignee: Emory University
    Inventors: Hanjoong Jo, Joan Fernandez Esmerats, Nicolas Villa-Roel
  • Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors
    Publication number: 20220090079
    Abstract: This disclosure relates to the use of miRNA-483 and its target genes, UBE2C, pVHL and HIF1alpha, in managing the treatment of cardiovascular and inflammatory diseases. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a miR-483 mimic and/or an HIF inhibitor and a pharmaceutically acceptable excipient for use in treating or preventing a vascular disease or condition. In certain embodiments, the miR-483 mimic is a double stranded nucleobase polymer or an expression vector that expresses mature human miR-483-5p and miR-483-3p sequences or operable fragments and variants.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 24, 2022
    Inventors: Hanjoong Jo, Joan Fernandez Esmerats, Nicolas Villa-Roel
  • Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors
    Patent number: 11225660
    Abstract: This disclosure relates to the use of miRNA-483 and its target genes, UBE2C, pVHL and HIF1alpha, in managing the treatment of cardiovascular and inflammatory diseases. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a miR-483 mimic and/or an HIF inhibitor and a pharmaceutically acceptable excipient for use in treating or preventing a vascular disease or condition. In certain embodiments, the miR-483 mimic is a double stranded nucleobase polymer or an expression vector that expresses mature human miR-483-5p and miR-483-3p sequences or operable fragments and variants.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: January 18, 2022
    Assignee: Emory University
    Inventors: Hanjoong Jo, Joan Fernandez Esmerats, Nicolas Villa-Roel
  • Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors
    Publication number: 20190112603
    Abstract: This disclosure relates to the use of miRNA-483 and its target genes, UBE2C, pVHL and HIF1alpha, in managing the treatment of cardiovascular and inflammatory diseases. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a miR-483 mimic and/or an HIF inhibitor and a pharmaceutically acceptable excipient for use in treating or preventing a vascular disease or condition. In certain embodiments, the miR-483 mimic is a double stranded nucleobase polymer or an expression vector that expresses mature human miR-483-5p and miR-483-3p sequences or operable fragments and variants.
    Type: Application
    Filed: October 10, 2018
    Publication date: April 18, 2019
    Inventors: Hanjoong Jo, Joan Fernandez Esmerats, Nicolas Villa-Roel